Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Here it is-
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154848/
I suspect a licencing deal is in the offing- been an awful long while since we heard on the chk1 front.
I'm not comparing so forgive if it looks that way.
The tyk2 jak1 approach is like the Chk1 in combo. By combining it with already FDA approved drugs it make them more effective as we have seen in the 80% tumour reduction data.
Bad example I know, also I think Sad mentioned Tyk2 being a potential for combo therapy.
I get your point, however, we are dual so can do Tyk2 as well, only we are claiming to be better by adding Jak1.
As a scientists once said if we have a safer and more efficient drug of the drug we already have it expands the market to those who would have been excluded from its benefits thereby replacing the existing drug and gaining its market share.
Https://go.drugbank.com/indications/DBCOND0039430/clinical_trials/DB00515?phase=1%2C2&status=completed
INDICATION- STATUS- PHASE
DBCOND0039430 (Advanced Solid Tumours) Completed 1 / 2
Are Cancer Research going to pull off an epic licencing deal?
Lets see how thing pan out.
Common Warthog, you must be bored we're in clinical trial and it's not free to run.
We'll get there don't worry but don't join the sealions your one of us and all those years of us collating patents etc. in readiness for this stage will pay off. You have to ask yourself why has the FDA approved Sotyktu without blackbox warnings, why is the NHS taking it up and why have Nimbus and Takeda struck a $4bn Tyk2 focused deal.
All eyes are on safer treatments /cures and Tyk2 fits that bill and we believe our route is even safer and effective.
'Sareum believes it provides clinical validation for this class of therapeutic, and for the broader TYK2/JAK1 signalling family, which underpins Sareum's clinical portfolio.
The Company believes the TYK2/JAK1 signalling pathway which it is pursuing offers potential for superior efficacy compared with agents, such as deucravacitinib, which block just one of the two kinases'.
Just a matter of time chap- the fud gave us no hope of getting to clinic posting tripe during Feb and March, but here we are.
Tyk2 is hot hot hot- so the BOD have done the best thing moving us to Aus and also said ph2 can be moved back to the UK or another territory in the investor meets and we've got a shiny new Chinese patent just for 1801.
Question to the long-termers is what are our thoughts on a ph2 in China, that said we also got a US auto-immune patent for 1802.
Aye Leggster, that what I initially thought hence why I said it threw me so wanted another pair of eye on it.
So we have got to 300mg in that case, so lets see what the safety committee announce and if it differs from this.
Lo and behold we are now a clinical stage company and not only that 1st dosed 6th June and 11wks into ph1a with a cohort increase to be announced Q3 by the safety committee.
So when not if in my opinion we get to ph1b efficacy and a major inflection point this lot of t..ts will be gone.
As we will have PK data tolerance and trial design data for ph1b for hospital patients and safety will be proven- the question is at what dosage and mtd will 1801 be used in all future trials then on in, that is what the industry and institutions what to see hence the inflection point.
Always loved that smile when she mentioned its progress. The key has always been the fact something is FDA approved so combining with it has the potential for fast-track approval and expands market size is toxicity is low to none existent.
Lets see how thing pan out- either chk1 licence or the endgame and total takeover
Something or nothing-
Our Chk1 and Prexasertib in combo-
https://www.nature.com/articles/s41416-023-02279-x
Prexasertib I believe is also used along with Olaratumab in STS-
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445779/#:~:text=Pediatric%20sarcoma%20cell%20lines%20were%20highly%20sensitive%20to%20prexasertib%20treatment,to%20prexasertib%20with%20complete%20regression.
Pediatric sarcoma cell lines were highly sensitive to prexasertib treatment in vitro, resulting in activation of the DNA damage response. Two PDX models of desmoplastic small round cell tumor and one malignant rhabdoid tumor CDX model responded to prexasertib with complete regression.
Now look at these numbers for Olaratumab-
Olaratumab is supplied as a sterile, preservative-free, clear to slightly opalescent, and colorless to slightly yellow solution.9 It is available in 19-mL and 50-mL vials containing 10 mg/1 mL with average wholesale prices of $1,098 and $2,889, respectively.
The FDA-approved dosing for STS patients is 15 mg/kg of IV olaratumab on days 1 and 8 every three weeks,
A70kg person would need 70x15= 1050mg
So 2large x $2889 (+ a bit) twice per cycle. So minimum about $12000 per cycle.
Blockbuster status for our Chk1 is a coming chaps in combo. The US has 13,000 and encouting STS patients insofar and that is just one country.
Can't remember precisely but was it 80% tumour reduction in combo?
It has blockbuster written all over it and to say CRUK started the trials in 2016 at the Royal Marsden and not too long after in Newcastle is testament to Chk1 and the SKIL Platform that created it, Aurora and the 2 Tyk2's.
Where all the t.ats today- bluenose you'll be pleased to know that I have bought another 2k worth at 79p 2525 to be exact a couple of moments ago so should appear in a mo.
Looking for to cohort increase the safety committee very soon.
I posted that last night and said that it looked like pharma were gearing up for covid part 2-
https://www.reuters.com/markets/deals/medical-tech-firm-danaher-buy-abcam-deal-valued-57-bln-2023-08-28/
Let the rainbow chasing begin- all bets are off on how far we could spike now that we are in clinic should have some positive news re. next cohort increase.
Aye carter, your not wrong there. Look at Synairgen and Novacyt in the past 2wks since this new covid news has been gathering pace.
Novacyt has seen a good move up and they are diagnostics based- we would be treating/curing it so you can imagine the rainbow chasers that will appear on here to spike the price.
Let's hope it doesn't go that way to be honest and we get 1801 to ph1b inflection point for the purposes we entered clinical trials for.
Apparently some part of a statement from the World Health Organisation today-
“ COVID-19 is here to stay, and the world will continue to need tools to prevent it, test for it and treat it,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
If Sar do decide to explore 1801 in ph1b or prior in covid then we can take heart that we as it inhibit IL-6 were on to a potential winner- This was posted last in 2021 by the WHO after our Covid research update in we mentiond being superior to dex but you could also say bari (as bari has tox issues) both esp. Dex are labelled lifesavers.
We also indicated going for bacterial pneumonia which again in that patent find was shown as targeting meaning all respiratory illnesses if we pull it off in ph1or ph1b.
https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access